# 2025-10503: DEA Proposes Scheduling a Hallucinogen With a Tongue-Twister Name

2025-10503, Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-[1-(3-methoxyphenyl)cyclohexyl]piperidine) in Schedule I, is a Federal Register proposed rule from Justice Department, Drug Enforcement Administration published 2025-06-10, effective Comments must be submitted electronically or postmarked on or before July 10, 2025.; PRIA reads it as touching household money (as of 2026-10-30).

- Canonical: https://policyrisk.com/federal-register/2025-10503
- As of: 2026-10-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-10503
- Title: Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-[1-(3-methoxyphenyl)cyclohexyl]piperidine) in Schedule I
- Type: Proposed Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 24370
- Published: 2025-06-10
- Effective: Comments must be submitted electronically or postmarked on or before July 10, 2025.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-30

## In one line

DEA Proposes Scheduling a Hallucinogen With a Tongue-Twister Name

## Summary

The DEA wants to put 3-methoxyphencyclidine, a hallucinogenic drug, into Schedule I, meaning it’s considered very risky with no accepted medical use. This change affects anyone who makes, sells, studies, or owns this drug, adding strict rules and penalties. You have until July 10, 2025, to share your thoughts before the new rules might kick in.

## Abstract

The Drug Enforcement Administration proposes placing 3- methoxyphencyclidine, including its salts, isomers, and salts of isomers, an arylcyclohexylamine hallucinogen, in schedule I of the Controlled Substances Act. This action is proposed to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess), or propose to handle 3-methoxyphencyclidine.

## Effects PRIA read

- 3‑MeO‑PCP placed in Schedule I: cost, high. The Drug Enforcement Administration proposes to place 3‑methoxyphencyclidine (3‑MeO‑PCP) and its salts and isomers in Schedule I of the Controlled Substances Act. If finalized, anyone who makes, sells, imports, exports, researches, or possesses 3‑MeO‑PCP would be treated as handling a Schedule I su…
- New registration and compliance duties: cost, medium. If the rule is finalized, persons who handle 3‑MeO‑PCP must register with DEA and follow Schedule I requirements including security rules, labeling and packaging rules, DEA‑assigned manufacturing quotas for registered manufacturers, order form rules, import/export controls, and recordkeeping/report…
- Authorized handling required or face penalties: cost, high. The proposal says any activity involving 3‑MeO‑PCP that is not authorized by the Controlled Substances Act or its regulations would be unlawful and may subject the person to administrative, civil, and/or criminal sanctions. That applies to manufacture, distribution, import/export, research, instruc…
- Agency says small entities not significantly harmed: benefit, low. DEA certifies under the Regulatory Flexibility Act that this proposed scheduling action "will not have a significant economic impact on a substantial number of small entities." DEA identified affected NAICS industries and reported counts and percent small firms, e.g., NAICS 325412: 1,007 firms, 931…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-21799](https://policyrisk.com/federal-register/2026-21799): Vida Janson, M.D.; Decision and Order, 2026-10-26
- [2026-21725](https://policyrisk.com/federal-register/2026-21725): Barry Backiewicz, D.D.S.; Decision and Order, 2026-10-26

## Sources
- [2025-10503 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/10/2025-10503/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine)
- [2025-10503 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-10/pdf/2025-10503.pdf)

## Related
- [Previous: 2025-10469, Updates to the Popcorn Promotion, Research, and Consumer Information Order](https://policyrisk.com/federal-register/2025-10469)
- [Next: 2025-10529, Establishment of Class E Airspace; Zuni, NM](https://policyrisk.com/federal-register/2025-10529)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-10503 (as of 2026-10-30).